COVID-19 | BioTuesdays

Developments

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported that its anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease. CRV431 demonstrated strong anti...

July 7, 2020

Developments

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Liminal BioSciences (NASDAQ, TSX:LMNL) provided a guidance update on the timing of certain expected key milestones for 2020. The company withdrew guidance in May because of the COVID-19 pandemic. In a statement, Kenneth...

July 1, 2020

Developments

Texas A&M video series features iBio COVID-19 vaccines

iBio’s (NYSE American:IBIO) two COVID-19 vaccine candidates were featured on the final episode of the video series, “COVID-19: The Texas A&M University System Responds.” “This is an important collaboration,” John...

June 26, 2020

Developments

Kamada IgG therapy cleared for compassionate COVID-19 use in Israel

Kamada (NASDAQ, TASE:KMDA) completed manufacturing of the first batch of its plasma-derived immunoglobulin (IgG) product for the treatment of COVID-19 and the initial vials are available for compassionate use in Israel...

June 17, 2020

Developments

PharmAust lab tests show positive signs for suppressing COVID-19

PharmAust (ASX:PAA) posted positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19. PharmAust, which traditionally is focused on repurposing existing drugs for cancer therapy, is...

June 4, 2020

Developments

iBio initiates second COVID-19 vaccine program

iBio (NYSE AMERICAN:IBIO) initiated preclinical immunization studies for its second COVID-19 vaccine platform with the potential for rapid manufacturing scale-up at its FastPharming System. The new subunit vaccine, IBIO...

June 4, 2020

Markets

BTIG starts Fulgent Genetics at buy; PT $20

BTIG initiated coverage of Fulgent Genetics (NASDAQ:FLGT) with a “buy” rating and $20 price target. The stock closed at $16.06 on May 28. Fulgent is a genetic testing service provider that has delivered more than...

May 29, 2020

Markets

Dawson James starts Sorrento Therapeutics at buy; PT $24

Dawson James Securities launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $24 price target. The stock closed at $5.07 on May 22. Analyst Jason Kolbert writes that Sorrento’s STI-1499...

May 26, 2020

Developments

Maxim ups Co-Diagnostics to buy; PT $30

Maxim Group upgraded Co-Diagnostics (NASDAQ:CODX) to “buy” from “hold” with a $30 price target, saying that COVID-19 testing has been transformative for the company. The stock closed at $18.85 on May 19. Co-Diagnostics...

May 20, 2020

Developments

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Closely-held PharmaJet’s needle-free injection system will be used to deliver a SARS-CoV mRNA vaccine being developed by Abnova, the world’s largest antibody vaccine manufacturer. “Our system has been found to improve...

May 19, 2020

Features

Spring Bank Pharma may expand R&D with potential COVID-19 agents

After abruptly ending its hepatitis B virus program in January, Spring Bank Pharmaceuticals (NASDAQ:SBPH) is in the early stages of examining whether its family of RIG-I agonists have the potential to attack SARS-CoV-2...

May 19, 2020

Features

COVID-19 presents opportunities and challenges for Field Trip Psychedelics

Despite delays in dosing of patients at its Toronto clinic and building its network of clinics in the U.S. because of COVID-19, closely-held Field Trip Psychedelics is finding opportunities to expand its psychedelic...

May 12, 2020

Hepion Pharma posts preclinical data supporting two-pronged approach treating COVID-19 with CRV431

Luminal BioSciences provides guidance on milestones; begins collecting plasma from COVID-19 recovered donors

Texas A&M video series features iBio COVID-19 vaccines

Kamada IgG therapy cleared for compassionate COVID-19 use in Israel

PharmAust lab tests show positive signs for suppressing COVID-19

iBio initiates second COVID-19 vaccine program

BTIG starts Fulgent Genetics at buy; PT $20

Dawson James starts Sorrento Therapeutics at buy; PT $24

Maxim ups Co-Diagnostics to buy; PT $30

PharmaJet partners with Abnova to develop needle-free COVID-19 vaccine

Spring Bank Pharma may expand R&D with potential COVID-19 agents

COVID-19 presents opportunities and challenges for Field Trip Psychedelics

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter